96 related articles for article (PubMed ID: 17507220)
21. Improved clearance of radioiodinated hypericin as a targeted anticancer agent by using a duodenal drainage catheter in rats.
Cona MM; Feng Y; Verbruggen A; Oyen R; Ni Y
Exp Biol Med (Maywood); 2013 Dec; 238(12):1437-49. PubMed ID: 24146264
[TBL] [Abstract][Full Text] [Related]
22. First Evaluation of Radioiodinated Flavonoids as Necrosis-Avid Agents and Application in Early Assessment of Tumor Necrosis.
Liang J; Sun Z; Zhang D; Jin Q; Cai L; Ma L; Liu W; Ni Y; Zhang J; Yin Z
Mol Pharm; 2018 Jan; 15(1):207-215. PubMed ID: 29226682
[TBL] [Abstract][Full Text] [Related]
23. Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations.
Cona MM; Li J; Feng Y; Chen F; Verbruggen A; Witte Pd; Oyen R; Ni Y
Anticancer Agents Med Chem; 2014; 14(6):852-61. PubMed ID: 24102315
[TBL] [Abstract][Full Text] [Related]
24. Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis.
Ji Y; Zhan Y; Jiang C; Jiang X; Gao M; Liu W; Li Y; Wang J; Wang Q; Cona MM; Yao N; Wang X; Fang Z; Yin Z; Zhang J; Sun Z; Ni Y
J Drug Target; 2014 May; 22(4):304-12. PubMed ID: 24328682
[TBL] [Abstract][Full Text] [Related]
25. Exploring diagnostic potentials of radioiodinated sennidin A in rat model of reperfused myocardial infarction.
Jiang C; Gao M; Li Y; Huang D; Yao N; Ji Y; Liu X; Zhang D; Wang X; Yin Z; Jing S; Ni Y; Zhang J
Int J Pharm; 2015 Nov; 495(1):31-40. PubMed ID: 26302863
[TBL] [Abstract][Full Text] [Related]
26. Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model.
Van de Putte M; Wang H; Chen F; De Witte PA; Ni Y
Oncol Rep; 2008 Apr; 19(4):927-32. PubMed ID: 18357377
[TBL] [Abstract][Full Text] [Related]
27. Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.
Cona MM; Alpizar YA; Li J; Bauwens M; Feng Y; Sun Z; Zhang J; Chen F; Talavera K; de Witte P; Verbruggen A; Oyen R; Ni Y
Pharm Res; 2014 Feb; 31(2):278-90. PubMed ID: 23934256
[TBL] [Abstract][Full Text] [Related]
28. Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy.
Gao L; Zhang J; Ma T; Yao N; Gao M; Shan X; Ni Y; Shao H; Xu K
Oncotarget; 2016 Aug; 7(32):51450-51461. PubMed ID: 27285983
[TBL] [Abstract][Full Text] [Related]
29. Experimental evaluation of radioiodinated sennoside B as a necrosis-avid tracer agent.
Zhang D; Huang D; Ji Y; Jiang C; Li Y; Gao M; Yao N; Liu X; Shao H; Jing S; Ni Y; Yin Z; Zhang J
J Drug Target; 2015 Feb; 23(2):180-90. PubMed ID: 25330022
[TBL] [Abstract][Full Text] [Related]
30. Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging.
Jiang B; Wang J; Ni Y; Chen F
Theranostics; 2013; 3(9):667-76. PubMed ID: 24052807
[TBL] [Abstract][Full Text] [Related]
31. Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.
Shao H; Zhang J; Sun Z; Chen F; Dai X; Li Y; Ni Y; Xu K
Oncotarget; 2015 Jun; 6(16):14247-59. PubMed ID: 26036625
[TBL] [Abstract][Full Text] [Related]
32. Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts.
Li J; Cona MM; Chen F; Feng Y; Zhou L; Zhang G; Nuyts J; de Witte P; Zhang J; Yu J; Oyen R; Verbruggen A; Ni Y
Theranostics; 2013; 3(2):127-37. PubMed ID: 23423247
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Radioiodinated 1,4-Naphthoquinones as Necrosis Avid Agents for Rapid Myocardium Necrosis Imaging.
Su C; Zhang D; Bao N; Ji A; Feng Y; Chen L; Ni Y; Zhang J; Yin Z
Mol Imaging Biol; 2018 Feb; 20(1):74-84. PubMed ID: 28470585
[TBL] [Abstract][Full Text] [Related]
34. Exploration of the mechanism underlying the tumor necrosis avidity of hypericin.
Van de Putte M; Ni Y; De Witte PA
Oncol Rep; 2008 Apr; 19(4):921-6. PubMed ID: 18357376
[TBL] [Abstract][Full Text] [Related]
35. Hypericin as a marker for determination of myocardial viability in a rat model of myocardial infarction.
Jiang C; Li Y; Jiang X; Yao N; Gao M; Zhang X; Wang J; Wang X; Sun Z; Zhang J; Ni Y
Photochem Photobiol; 2014; 90(4):867-72. PubMed ID: 24460608
[TBL] [Abstract][Full Text] [Related]
36. Necrosis affinity evaluation of 131I-hypericin in a rat model of induced necrosis.
Kong M; Zhang J; Jiang C; Jiang X; Li Y; Gao M; Yao N; Huang D; Wang X; Fang Z; Liu W; Sun Z; Ni Y
J Drug Target; 2013 Jul; 21(6):604-10. PubMed ID: 23627568
[TBL] [Abstract][Full Text] [Related]
37. A novel method for the detection of necrotic lesions in human cancers.
Epstein AL; Chen FM; Taylor CR
Cancer Res; 1988 Oct; 48(20):5842-8. PubMed ID: 3048650
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and Evaluation of
Wang C; Jin Q; Yang S; Zhang D; Wang Q; Li J; Song S; Sun Z; Ni Y; Zhang J; Yin Z
Mol Pharm; 2016; 13(1):180-189. PubMed ID: 26647005
[TBL] [Abstract][Full Text] [Related]
39. Excretion and toxicity evaluation of
Yin Z; Sun L; Jin Q; Song S; Feng Y; Liao H; Ni Y; Zhang J; Liu W
Xenobiotica; 2017 Nov; 47(11):980-988. PubMed ID: 27830982
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
